Taurine: A Potential Novel Addition to the Anti-Systemic Sclerosis Weaponry

Archives of Medical Research

Volumn 41, Issue 1, 2010, Pages 59-61

  Fallahzadeh, Mohammad Kazem ^a   Namazi, Mohammad Reza ^b   Gupta, Ramesh C ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NAGALAND UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN; SUPEROXIDE; TAURINE; TAURINE CHLORAMINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; COLLAGEN SYNTHESIS; CYTOKINE PRODUCTION; DRUG MECHANISM; ENDOTHELIUM LESION; GENE EXPRESSION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; SKIN FIBROSIS; SPINAL CORD INJURY; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL; VASCULAR ENDOTHELIUM;

HUMANS; SCLERODERMA, SYSTEMIC; TAURINE;

EID: 77952322463     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.11.005     Document Type: Article

References (25)

1. Denton CP. Pathogenesis of systemic sclerosis (scleroderma). Uptodate 17.1 online. 2009. [cited: May 29, 2009] Available from: http://www.uptodate.com/online/content/topic.do?topicKey=sclerode/7049&selectedTitle=2~150&source=search_result.
2. Yazawa N., Fujimoto M., Tamaki K. Recent advances on pathogenesis and therapies in systemic sclerosis. Clin Rev Allergy Immunol 2007, 33:107-112.
3. Bruckdorfer K.R., Hillary J.B., Bunce T., et al. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995, 38:1060-1067.
4. Hussein M.R., Hassan H.I., Hofny E.R., et al. Alterations of mononuclear inflammatory cells, CD4/CD8 + T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005, 58:178-184.
5. Schuller-Levis G.B., Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res 2004, 29:117-126.
6. Verner A., Craig S., McGuire W. Effect of taurine supplementation on growth and development in preterm or low birth weight infants. Cochrane Database Syst Rev 2007, (4). CD006072.
7. Gray G.E., Landel A.M., Meguid M.M. Taurine-supplemented total parenteral nutrition and taurine status of malnourished cancer patients. Nutrition 1994, 10:11-15.
8. Zhao X., Jia J., Lin Y. Taurine content in Chinese food and daily intake of Chinese men. Adv Exp Med Biol 1998, 442:501-505.
9. Rana S.K., Sanders T.A. Taurine concentrations in the diet, plasma, urine and breast milk of vegans compared with omnivores. Br J Nutr 1986, 56:17-27.
10. Alford C., Cox H., Wescott R. The effects of Red Bull energy drink on human performance and mood. Amino Acids 2001, 21:139-150.
11. Santangelo F. The regulation of sulphurated amino acid junctions: fact or fiction in the field of inflammation?. Amino Acids 2002, 23:359-365.
12. Cortijo J., Cerdá-Nicolás M., Serrano A., et al. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J 2001, 17:1228-1235.
13. Nakajima Y., Osuka K., Seki Y., et al. Taurine reduces inflammatory responses after spinal cord injury. J Neurotrauma 2009, [Epub ahead of print].
14. Marcinkiewicz J., Głuszko P., Kontny E., et al. Is Taurolidine a candidate for treatment of rheumatoid arthritis?. Clin Exp Rheumatol 2007, 25:211-218.
15. Barua M., Liu Y., Quinn M.R. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: decreased NF-kappaB activation and IkappaB kinase activity. J Immunol 2001, 167:2275-2281.
16. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 2009, 87:91-99.
17. Ulrich-Merzenich G., Zeitler H., Vetter H., et al. Protective effects of taurine on endothelial cells impaired by high glucose and oxidized low density lipoproteins. Eur J Nutr 2007, 46:431-438.
18. Yamamoto T., Takagawa S., Katayama I., et al. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999, 113:843-847.
19. Chorazy M., Kontny E., Marcinkiewicz J., et al. Taurine chloramine modulates cytokine production by human peripheral blood mononuclear cells. Amino Acids 2002, 23:407-413.
20. Quinn M.R., Park E., Schuller-Levis G. Taurine chloramine inhibits prostaglandin E2 production in activated RAW 264.7 cells by post-transcriptional effects on inducible cyclooxygenase expression. Immunol Lett 1996, 50:185-188.
21. Namazi M.R. The beneficial and detrimental effects of linoleic acid on autoimmune disorders. Autoimmunity 2004, 37. 73-57.
22. Cruz C.I., Ruiz-Torres P., del Moral R.G., et al. Age-related progressive renal fibrosis in rats and its prevention with ACE inhibitors and taurine. Am J Physiol Renal Physiol 2000, 278:F122-F129.
23. Shirahige A., Mizushima T., Matsushita K., et al. Oral administration of taurine improves experimental pancreatic fibrosis. J Gastroenterol Hepatol 2008, 23:321-327.
24. Gurujeyalakshmi G., Wang Y., Giri S.N. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-κB in mice. J Pharmacol Exp Ther 2000, 293:82-90.
25. Miyazaki T., Karube M., Matsuzaki Y., et al. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. J Hepatol 2005, 43:117-125.